Japan's Medtech Major Terumo Buys UK's OrganOx for $1.5 Bn

By combining OrganOx’s deep clinical expertise with Terumo’s scale and distribution network, the partnership aims to accelerate innovation in organ-support solutions.

Japanese medical-technology leader Terumo Corporation has completed the acquisition of U.K.-based organ-preservation specialist OrganOx Ltd for $1.5 Billion, following satisfaction of all customary regulatory and closing conditions.

The deal, which was first announced in September, makes OrganOx a wholly-owned subsidiary of Terumo.

The deal integrates OrganOx’s pioneering normothermic machine perfusion (NMP) platform, the Metra system used for preserving and assessing donor organs, with Terumo’s global scale, medical-device expertise and commercial reach.

By combining OrganOx’s deep clinical expertise with Terumo’s scale and distribution network, the partnership aims to accelerate innovation in organ-support solutions.

The collaboration is expected to advance further research and development for evolving the metra platform beyond liver transplantation and explore wider applications of NMP across multiple organs, which can extend preservation time, improve organ viability, and increase successful transplant rates worldwide.

Commenting on the acquisition, OrganOx CEO Craig Marshall said, “Our mission has always been to create a world where every organ counts. Joining Terumo will accelerate our ability to scale our operations more rapidly, enter new markets and ensure that more patients around the globe can benefit from our technologies.”

“This milestone reflects the extraordinary dedication of our team, whose commitment to innovation and patient outcomes brought OrganOx to this point. With Terumo’s partnership, we’re positioned to deliver even greater growth and impact,” he further added.

Founded in 2008 by University of Oxford professors Peter Friend and Constantin Coussios, the company had generated sales of approximately £ 55.2 million in 2024. Its patented technology enables extending organ preservation time and allows for real-time monitoring during storage and transport, thereby improving transplant outcomes, including those from marginal donors.

With this investment, OrganOx will also have access to Terumo’s global network, which is anticipated to accelerate commercial growth and extend its reach into new markets.

Stay tuned for more such updates on Digital Health News